Biofrontera Announces Database Lock Of Phase 3 Study Of Ameluz-Photodynamic Therapy In The Treatment Of Superficial Basal Cell Carcinoma; The Last Patient Is Expected To Complete Follow Up By December Of This Year, And Submission Is Targeted For Q1 2025
Portfolio Pulse from Benzinga Newsdesk
Biofrontera Inc. has announced the database lock for its Phase 3 study of Ameluz-Photodynamic Therapy in treating superficial basal cell carcinoma. The study's data is now ready for analysis, with interim results expected in November 2024. The final submission to the FDA is targeted for Q1 2025.
October 14, 2024 | 2:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Biofrontera Inc. has reached a significant milestone by locking the database for its Phase 3 study of Ameluz-PDT for sBCC treatment. This marks the end of data collection, with interim results expected in November 2024 and FDA submission planned for Q1 2025.
The database lock is a critical milestone in clinical trials, indicating readiness for data analysis. Positive interim results could boost investor confidence, potentially driving the stock price up. The planned FDA submission in Q1 2025 further adds to the potential positive impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100